5
Orphan Designations
0 approved, 5 designated
0
FDA Approvals
0
Active Trials
200 recruiting
5
Rare Diseases
across 9 areas
0
News (30d)
Quiet
Rexahn Corporation is a company with 5 orphan drug designations across 5 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| gastric carcinoma | 20-mer complementary to Akt mRNA | Des.TrialAppr. |
| glioblastoma | 20-mer oligonucleotide complementary to Akt mRNA | Des.TrialAppr. |
| malignant pancreatic neoplasm | 20-mer oligonucleotide complementary to Akt mRNA | Des.TrialAppr. |
| ovarian cancer | 20-mer oligonucleotide complementary to Akt mRNA | Des.TrialAppr. |
| renal cell carcinoma | 20-mer oligonucleotide complementary to Akt mRNA | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
48
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
48
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio